Hypoxia in solid tumors is an important predictor of poor clinical outcome to radiotherapy.
Both physicochemical and biological processes contribute to a reduced sensitivity of hypoxic …

In contemporary oncology, radiation therapy and immunotherapy stand as critical
treatments, each with distinct mechanisms and outcomes. Radiation therapy, a key player in …

Background and purpose Recent progress in diagnostics and treatment of metastatic cancer
patients have improved survival substantially. These developments also affect local …

Novel systemic therapies for breast cancer are being rapidly implemented into clinical
practice. These drugs often have different mechanisms of action and side-effect profiles …

Purpose Given the unique features of the liver, it is necessary to combine immunotherapy
with other therapies to improve its efficacy in patients of advanced cancer with liver …

Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer
(NSCLC). Oligometastasis has been associated with better prognosis than widespread …

The combined use of stereotactic ablative radiotherapy (SABR) and immune checkpoint
inhibitors (ICIs) is an emerging treatment paradigm for oligometastatic non-small-cell lung …

Progresses of systemic treatments in advanced non-small cell lung cancer (NSCLC), such
as immune checkpoint blockers (ICB) and targeted therapies, led to the increased incidence …

Background Accurate evaluation of the response to preoperative treatment enables the
provision of a more appropriate personalized therapeutic schedule for locally advanced …

Immune evasion is a key phenomenon in understanding tumor recurrence, metastasis, and
other critical steps in tumor progression. The tumor microenvironment (TME) is in constant …